For patients with advanced renal cell carcinoma, progression-free survival and overall survival are improved with lenvatinib plus pembrolizumab versus sunitinib, according to a study. Toni K. Choueiri, M.D. and colleagues conducted a protocol-prespecified updated overall survival analysis of the phase 3 CLEAR trial. Patients with clear-cell advanced renal cell carcinoma who had not received any systemic anticancer therapy were eligible and randomly assigned to receive lenvatinib plus pembrolizumab, lenvatinib plus everolimus, or sunitinib (355, 357, and 357, respectively). This updated analysis did not report on patients in the lenvatinib plus everolimus group. The median follow-up for progression-free survival was 27.8...